The update interpretation of 2020 EAU renal cell carcinoma guideline(Part Ⅱ) / 中华泌尿外科杂志

ABSTRACT

The highlight of the 2020 EAU guideline updates on the systemic therapy for advanced and metastatic renal cell carcinoma is that monotherapy tyrosine kinase inhibitors, e.g. sunitinib, pazopanib, cabozantinib are not recommended as fist line treatment option for clear-cell metastatic renal cell carcinoma. Instead, immune checkpoint inhibitor combination therapy becomes the first choice for these patients. However, the targeted therapies can be offered as second-line therapy to patients refractory to pembrolizumab plus axitinib or nivolumab plus ipilimumab.